标题
Systemic treatment options for advanced biliary tract carcinoma
作者
关键词
-
出版物
JOURNAL OF GASTROENTEROLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-08-03
DOI
10.1007/s00535-020-01712-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.
- (2020) Juan W. Valle et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of futibatinib (TAS-120) in patients (pts) with advanced (adv) solid tumors harboring fibroblast growth factor receptor (FGFR) genomic aberrations.
- (2020) Antoine Hollebecque et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic therapies for intrahepatic cholangiocarcinoma
- (2020) Robin Kate Kelley et al. JOURNAL OF HEPATOLOGY
- Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
- (2020) Akihiro Ohba et al. JOURNAL OF CLINICAL ONCOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program
- (2019) Markus Moehler et al. BMC CANCER
- Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts
- (2019) C. B. Westphalen et al. Clinical & Translational Oncology
- Cholangiocarcinoma: Epidemiology and risk factors
- (2019) Shahid A. Khan et al. LIVER INTERNATIONAL
- Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
- (2019) Paola Bertuccio et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.
- (2019) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
- (2019) Tatsuya Ioka et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
- (2019) Joon Oh Park et al. JOURNAL OF CLINICAL ONCOLOGY
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- (2019) Angela Lamarca et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from TRK Inhibitor Therapy
- (2019) Susan J. Hsiao et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
- (2019) Rachna T. Shroff et al. JAMA Oncology
- Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
- (2019) Danielle Golub et al. Frontiers in Oncology
- O-005Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial
- (2019) J Harding et al. ANNALS OF ONCOLOGY
- Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
- (2019) Maeve A Lowery et al. Lancet Gastroenterology & Hepatology
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
- (2019) C Morizane et al. ANNALS OF ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
- (2019) Martin Schuler et al. LANCET ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Cholangiocarcinoma: anatomical location-dependent clinical, prognostic, and genetic disparities
- (2019) Hualian Hang et al. Annals of Translational Medicine
- O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
- (2018) F Meric-Bernstam et al. ANNALS OF ONCOLOGY
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States
- (2018) Shiva Kumar R. Mukkamalla et al. Journal of the National Comprehensive Cancer Network
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- (2018) Yiyi Yan et al. Frontiers in Immunology
- 615ORandomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)
- (2018) D Sakai et al. ANNALS OF ONCOLOGY
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
- (2018) Weijing Sun et al. CANCER
- Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers
- (2018) Maeve A. Lowery et al. CLINICAL CANCER RESEARCH
- Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer
- (2018) Changqing Xie et al. HEPATOLOGY
- Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
- (2018) James J. Harding et al. Cancer Discovery
- Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers
- (2017) Marie Bréchon et al. INVESTIGATIONAL NEW DRUGS
- Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
- (2017) Tomohiro Nishina et al. INVESTIGATIONAL NEW DRUGS
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Cholangiocarcinoma — evolving concepts and therapeutic strategies
- (2017) Sumera Rizvi et al. Nature Reviews Clinical Oncology
- Overall Survival and Clinical Characteristics of BRCA‐Associated Cholangiocarcinoma: A Multicenter Retrospective Study
- (2017) Talia Golan et al. ONCOLOGIST
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- New Horizons for Precision Medicine in Biliary Tract Cancers
- (2017) Juan W. Valle et al. Cancer Discovery
- A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
- (2016) John Bridgewater et al. BMC CANCER
- HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
- (2016) Salvatore Galdy et al. CANCER AND METASTASIS REVIEWS
- Therapeutic implication of HER2 in advanced biliary tract cancer
- (2016) Ah-Rong Nam et al. Oncotarget
- Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma
- (2015) Finn Ole Larsen et al. ACTA ONCOLOGICA
- A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
- (2015) J. S. Chen et al. ANNALS OF ONCOLOGY
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-typeKRASadvanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
- (2015) Francesco Leone et al. CANCER
- Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): Safety, efficacy, and updated translational results.
- (2015) Cindy Neuzillet et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2/neu-directed therapy for biliary tract cancer
- (2015) Milind Javle et al. Journal of Hematology & Oncology
- Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
- (2015) Juan W Valle et al. LANCET ONCOLOGY
- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma
- (2015) Jean-Florian Guion-Dusserre et al. WORLD JOURNAL OF GASTROENTEROLOGY
- A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
- (2014) S. Pant et al. ANNALS OF ONCOLOGY
- A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
- (2014) A. Santoro et al. ANNALS OF ONCOLOGY
- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)
- (2014) Masashi Kanai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cholangiocarcinoma
- (2014) Nataliya Razumilava et al. LANCET
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
- (2014) David Malka et al. LANCET ONCOLOGY
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
- (2014) Chaitanya R. Churi et al. PLoS One
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma
- (2014) Xiao-Qing Yang WORLD JOURNAL OF GASTROENTEROLOGY
- Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
- (2014) Mitesh J. Borad et al. PLoS Genetics
- Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma
- (2014) Michael N. Mavros et al. JAMA Surgery
- Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology
- (2013) I. Borbath et al. ANNALS OF ONCOLOGY
- A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
- (2013) D. P. S. Sohal et al. ANNALS OF ONCOLOGY
- A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
- (2013) J K Lee et al. BRITISH JOURNAL OF CANCER
- Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: A phase 2 study
- (2013) G. Rubovszky et al. EUROPEAN JOURNAL OF CANCER
- Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
- (2013) Sumera Rizvi et al. GASTROENTEROLOGY
- BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
- (2013) Benjamin Goeppert et al. MODERN PATHOLOGY
- HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib
- (2012) Joshua Peck et al. ONCOLOGY
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
- (2011) M Miyamoto et al. BRITISH JOURNAL OF CANCER
- A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
- (2011) Jun Ho Yi et al. EUROPEAN JOURNAL OF CANCER
- SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
- (2011) Anthony B. El-Khoueiry et al. INVESTIGATIONAL NEW DRUGS
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
- (2010) Birgit Gruenberger et al. LANCET ONCOLOGY
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
- (2009) C Bengala et al. BRITISH JOURNAL OF CANCER
- A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
- (2009) Ramesh K. Ramanathan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Trial of Gemcitabine Combined with 5-fluorouracil and Cisplatin (GFP) Chemotherapy in Patients with Advanced Biliary Tree Cancers
- (2009) Y.-i. Yamashita et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
- (2009) Andrew X Zhu et al. LANCET ONCOLOGY
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now